Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Abb. 0: FÜR ÖSTERREICH: Weitere Informationen: Servier, Mariahilfer Straße 20/5, 1070 Wien, Tel. 01/524 39 99 Abb. 1: EUROPA-Studie Abb. 2: Studientrends - ACE-Hemmer Aktuelles Bild - Abb. 3: ACE-Hemmung - Benefit Abb. 4: KHK - Sekundärprävention Abb. 5: KHK - Sekundärprävention Abb. 6: Endotheliale Dysfunktion Zum letzten Bild
Abbildung 3: ACE-Hemmung - Benefit
So far, the benefit of ACE inhibitors were extensively investigated in large cohort of ishemic heart disease patients: post MI, LVSD with EF < 40 %, HF. The difference between these trials lies in the type of patients selected for each respective trial, which are actually patients of high risk. Coronary artery disease is a progressive condition involving patients with lower and higher risk levels. For cardiologists, according to the investigators from the EUROPA trial, patients involved presented all-risk coronary patients in comparison to other trials conducted in this area, which were patients considered as high risk patients. So, EUROPA was aiming to resolve the question on the benefits of ACE inhibition in the treatment of all risk stable coronary artery disease patients.
 
ACE-Hemmung - Benefit
Vorheriges Bild Nächstes Bild   


Abbildung 3: ACE-Hemmung - Benefit
So far, the benefit of ACE inhibitors were extensively investigated in large cohort of ishemic heart disease patients: post MI, LVSD with EF < 40 %, HF. The difference between these trials lies in the type of patients selected for each respective trial, which are actually patients of high risk. Coronary artery disease is a progressive condition involving patients with lower and higher risk levels. For cardiologists, according to the investigators from the EUROPA trial, patients involved presented all-risk coronary patients in comparison to other trials conducted in this area, which were patients considered as high risk patients. So, EUROPA was aiming to resolve the question on the benefits of ACE inhibition in the treatment of all risk stable coronary artery disease patients.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung